WO1995024894A3 - Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents - Google Patents

Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents Download PDF

Info

Publication number
WO1995024894A3
WO1995024894A3 PCT/US1995/003337 US9503337W WO9524894A3 WO 1995024894 A3 WO1995024894 A3 WO 1995024894A3 US 9503337 W US9503337 W US 9503337W WO 9524894 A3 WO9524894 A3 WO 9524894A3
Authority
WO
WIPO (PCT)
Prior art keywords
epithelial cell
subject
derivatives
lipoxygenase inhibitors
derived cancer
Prior art date
Application number
PCT/US1995/003337
Other languages
French (fr)
Other versions
WO1995024894A9 (en
WO1995024894A2 (en
Inventor
James L Mulshine
Marti Jett
Original Assignee
Us Health
James L Mulshine
Marti Jett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, James L Mulshine, Marti Jett filed Critical Us Health
Priority to EP95916100A priority Critical patent/EP0750496A1/en
Priority to US08/704,569 priority patent/US6071949A/en
Priority to AU22722/95A priority patent/AU698313B2/en
Publication of WO1995024894A2 publication Critical patent/WO1995024894A2/en
Publication of WO1995024894A9 publication Critical patent/WO1995024894A9/en
Publication of WO1995024894A3 publication Critical patent/WO1995024894A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present method provides a method for treating an epithelial cell-derived cancer in a subject in need of such treatment which comprises administering to the subject an amount of a 5-lipoxygenase inhibitor or derivative thereof effective to treat the epithelial cell-derived cancer. The present invention also provides a method for preventing an epithelial cell-derived cancer in a subject in need of such prevention which comprises administering to the subject an amount of a 5-lipoxygenase inhibitor effective to prevent the epithelial cell-derived cancer. Suitable 5-lipoxygenase inhibitors useful for the methods of the present invention preferably include 2-(12-Hydroxydodeca-5,10-dinyl)-3,5,6-trimethyl-1,4-benzoquinone and derivatives thereof; Nordihydroguaiaretic acid and derivatives; and 3-[1-(4-chlorobenzyl)-3-t-butyl-thio-t-isopropyl-indol-2-yl]-2-2-dimethylpropanoic acid and derivatives thereof. Also intended to be encompassed by this invention are hydroxyurea derivatives as inhibitors of 5-lipoxygenase inhibitors for use in the prevention and treatment of epithelial cell-derived cancers.
PCT/US1995/003337 1994-03-14 1995-03-14 Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents WO1995024894A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95916100A EP0750496A1 (en) 1994-03-14 1995-03-14 Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US08/704,569 US6071949A (en) 1995-03-14 1995-03-14 Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
AU22722/95A AU698313B2 (en) 1994-03-14 1995-03-14 Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21207494A 1994-03-14 1994-03-14
US08/212,074 1994-03-14

Publications (3)

Publication Number Publication Date
WO1995024894A2 WO1995024894A2 (en) 1995-09-21
WO1995024894A9 WO1995024894A9 (en) 1995-10-26
WO1995024894A3 true WO1995024894A3 (en) 1995-12-21

Family

ID=22789451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/003337 WO1995024894A2 (en) 1994-03-14 1995-03-14 Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents

Country Status (4)

Country Link
EP (1) EP0750496A1 (en)
AU (1) AU698313B2 (en)
CA (1) CA2185448A1 (en)
WO (1) WO1995024894A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624704A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkanoic acid amides
DE19624659A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkene and pyridylalkanoic acid amides
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19756235A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
DE19756261A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New aryl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756236A1 (en) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756212A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New cyclic imide-substituted pyridylalkane, alkene and alkyarboxylic acid amides
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
WO2010124283A2 (en) 2009-04-24 2010-10-28 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
US20150216820A1 (en) 2012-09-07 2015-08-06 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138464A2 (en) * 1983-10-03 1985-04-24 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
EP0259972A2 (en) * 1986-08-08 1988-03-16 Lilly Industries Limited Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
EP0269017A2 (en) * 1986-11-21 1988-06-01 Cetus Oncology Corporation Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
WO1988003805A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
EP0459748A2 (en) * 1990-06-01 1991-12-04 Lilly Industries Limited Thien-2-yl methylurea derivatives as leukotriene inhibitors
WO1992009567A1 (en) * 1990-11-23 1992-06-11 The Wellcome Foundation Limited Anti-inflammatory compounds
WO1995000129A1 (en) * 1993-06-23 1995-01-05 Chemex Pharmaceuticals Inc. Treatment of multidrug resistant diseases

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138464A2 (en) * 1983-10-03 1985-04-24 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
EP0259972A2 (en) * 1986-08-08 1988-03-16 Lilly Industries Limited Heterocyclic propene amide derivatives, processes for their preparation and their use as pharmaceuticals
WO1988003026A1 (en) * 1986-10-28 1988-05-05 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
WO1988003805A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
EP0269017A2 (en) * 1986-11-21 1988-06-01 Cetus Oncology Corporation Therapeutic combination of free-radical scavenger or metabolic inhibitor and biologically active protein
EP0459748A2 (en) * 1990-06-01 1991-12-04 Lilly Industries Limited Thien-2-yl methylurea derivatives as leukotriene inhibitors
WO1992009567A1 (en) * 1990-11-23 1992-06-11 The Wellcome Foundation Limited Anti-inflammatory compounds
WO1995000129A1 (en) * 1993-06-23 1995-01-05 Chemex Pharmaceuticals Inc. Treatment of multidrug resistant diseases

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
A.RICHTER ET AL.: "Inhibition of growth of carcinoma cells by inhibitors of 5-lipoxygenase", BR.J.CANCER, vol. 62, no. 3, September 1990 (1990-09-01), pages 537 *
A.W.FORD-HUTCHINSON: "Regulation of leukotriene biosynthesis", CANCER METASTASIS REV., vol. 13, no. 3-4, December 1994 (1994-12-01), pages 257 - 267 *
C.R.SMART ET AL.: "AN INTERESTING OBSERVATION ON NORDIHYDROGUAIARETIC ACID (NSC-4291; NDGA) AND A PATIENT WITH MALIGNANT MELANOMA - A PRELIMINARY REPORT", CANCER CHEMOTHER.REP., vol. 53, no. 2PT1, 1969, pages 147 - 151 *
C.R.SMART ET AL.: "Clinical experience with nordihydroguaiaretic acid - -", ROCKY MT.MED.J., vol. 67, no. 11, November 1970 (1970-11-01), pages 39 - 43 *
DIALOG INFORMATION SYSTEMS, FILE 159: CANCERLIT, ACCESSION NUMBER 00721305 *
F.ONDREY ET AL.: "Cell membrane fluidity and the inhibition of cell division by ETYA or NDGA", PROC.AM.ASSOC.CANCER RES.ANNU.MEET., vol. 30, 1989, pages 15 *
G.FÜRSTENBERGER ET AL.: "Phorbol ester-induced leukotriene biosynthesis and tumor promotion in mouse epidermis", CARCINOGENESIS, vol. 15, no. 12, December 1994 (1994-12-01), pages 2823 - 2827 *
G.K.REID ET AL.: "Correlation between Expression of 5-Lipoxygenase-activating Protein, 5-Lipoxygenase, and Cellular Leukotriene Synthesis", J.BIOL.CHEM., vol. 265, no. 32, 15 November 1990 (1990-11-15), pages 19818 - 19823 *
I.A.TAVARES ET AL.: "Tamoxifen inhibits 5-lipoxygenase in human polymorphonuclear leucocytes", J.PHARM.PHARMACOL., vol. 39, no. 4, April 1987 (1987-04-01), pages 323 - 324 *
I.AVIS ET AL.: "The effect of arachidonic acid metabolites and lipoxygenase pathway inhibitors on the in vitro growth of human lung cancer cell lines", PROC.ANNU.MEET.AM.ASSOC.CANCER RES., vol. 35, March 1994 (1994-03-01), pages 618 *
I.GÁTI ET AL.: "Effects of the 5-Lipoxygenase Inhibitors AA-683 and U-60,257 on Human Glioma Cell Lines", PROSTAGLANDINS LEUKOT.ESSENT.FATTY ACIDS, vol. 40, no. 2, June 1990 (1990-06-01), pages 117 - 124 *
I.M.GROSSI: "Platelet and Tumor Cell Derived 12(S)-HETE Enhances Endothelial Cell Retraction and Tumor Cell Adhesion to Subendothelial Matrix", PROC.ANNU.MEET.AM.ASSOC.CANCER RES., vol. 31, 1990, pages 65 *
J.R.HECHT ET AL.: "ZILEUTON INHIBITS PROLIFERATION OF HT-29 CELLS", GASTROENTEROLOGY, vol. 104, no. 4SUP, 1993, pages A408 *
K.M.ANDERSON ET AL.: "Pc-3 Prostate Cell DNA-Synthesis is Suppressed by ETYA and NDGA, Inhibitors of Eicosanoid Biosynthesis", PROC.ANNU.MEET.AM.ASSOC.CANCER RES., vol. 28, 1987, pages 66 *
M.PAVANI ET AL.: "INHIBITION OF TUMORAL CELL RESPIRATION AND GROWTH BY NORDIHYDROGUAIARETIC ACID", BIOCHEMICAL PHARMACOLOGY, vol. 48, no. 10, 1994, pages 1935 - 1942 *
M.R.STEINER ET AL.: "Inhibitors of Phospholipase A2 and Eicosanoid Biosynthesis in Cancer", DRUG NEWS PERSPECT., vol. 7, no. 6, August 1994 (1994-08-01), pages 344 - 351 *
P.A.NARDONE ET AL.: "Ketoconazole: A Thromboxane Synthetase and 5-Lipoxygenase Inhibitor with Antimetastatic Activity in B16-F10 Melanoma", J.SURG.RES., vol. 44, no. 4, April 1988 (1988-04-01), pages 425 - 429 *
R.K.RALPH ET AL.: "Inhibitors of lipoxygenase have antiproliferative effects on P815 murine mastocytoma cells", CANCER LETT., vol. 49, no. 3, March 1990 (1990-03-01), pages 181 - 185 *
R.K.RALPH ET AL.: "Inhibitors of lipoxygenase have antiproliferative effects on P815 murine mastocytoma cells", CANCER LETTERS, vol. 49, no. 3, March 1990 (1990-03-01), pages 181 - 185 *
R.L.FINE ET AL.: "5-S-Hydroxyeicosatetraenoic acid: A novel growth factor for malignant and normal cells.", PROC.ANNU.MEET.AM.ASSOC.CANCER RES., vol. 32, 1991, pages 49 *
R.L.FINE ET AL.: "Inhibition of 5-Lipoxygenase (5-LIPOX) induces cell quiescence of multidrug-resistant (MDR) and sensitive human breast cancer cells.", PROC.ANNU.MEET.AM.ASSOC.CANCER RES., vol. 31, 1990, pages 55 *
S.BITTER ET AL.: "Glucocorticoid-Induced Lymphoma Cell Growth Inhibition: The Role of Leukotriene B4", ENDOCRINOLOGY, vol. 123, no. 2, 1988, pages 991 - 1000 *
S.KARGMAN ET AL.: "A23187-Induced Translocation of 5-Lipoxygenase in Osteosarcoma Cells", J.CELL BIOL., vol. 119, no. 6, December 1992 (1992-12-01), pages 1701 - 1710 *
T.NAKADATE ET AL.: "INHIBITION BY LIPOXYGENASE INHIBITORS OF 7-BROMOMETHYLBENZ[A]ANTHRACENE-CAUSED EPIDERMAL ORNITHINE DECARBOXYLASE INDUCTION AND SKIN TUMOR PROMOTION IN MICE", CARCINOGENESIS, vol. 10, no. 11, 1989, pages 2053 - 2057 *
T.SCHAUB ET AL.: "ATP-dependent leukotriene export from mastocytoma cells", FEBS LETT., vol. 279, no. 1, 11 February 1991 (1991-02-11), pages 83 - 86 *
V.C.DIAS ET AL.: "Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2)", GUT, vol. 33, no. 5, May 1992 (1992-05-01), pages 622 - 627 *
W.DAWSON ET AL.: "5-Lipoxygenase Inhibition in Relation to Cell Movement and Cancer", ICOSANOIDS AND CANCER (H.THALER-DAO ET AL., EDS), 1984, RAVEN PRESS, NEW YORK, pages 229 - 234 *

Also Published As

Publication number Publication date
CA2185448A1 (en) 1995-09-21
WO1995024894A2 (en) 1995-09-21
EP0750496A1 (en) 1997-01-02
AU698313B2 (en) 1998-10-29
AU2272295A (en) 1995-10-03

Similar Documents

Publication Publication Date Title
WO1995024894A3 (en) Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
MY134841A (en) Substituted pyridines as selective cyclooxygenase-2 inhibitors
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
AU2713500A (en) Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
PL347469A1 (en) Use of certain drugs for treating nerve root injury
AP2002002596A0 (en) Piperazine and piperidine derivatives.
BR9814923A (en) Method for treating alzheimer's disease
DE60121440D1 (en) CANCER TREATMENT COMPOSITION CONTAINING AN ANTINEOPLASTIC AGENT AND PDE4 INHIBITOR
WO2005030753A3 (en) Therapeutic agents useful for treating pain
HK1014440A1 (en) Trisubstituted phenyl derivatives
GR3031917T3 (en) Treatment of diseases caused by sebaceous gland disorders with acyl CoA cholesterol acyl transferase inhibitors
WO2002057222A3 (en) Thiol-based naaladase inhibitors
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
EP1178796A4 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
CA2270469A1 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
MXPA04001398A (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine.
NO20003848L (en) Method of Treating Follicular Lymphoma Using Lymphotoxin (LT) Pathway Inhibitors
WO2005042718A3 (en) Compositions and methods for treating, preventing, reversing and inhibiting pain
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/11,2/11,4/11-11/11,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2185448

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995916100

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08704569

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995916100

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995916100

Country of ref document: EP